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Edited by Frances ShannonAbstract Echinacea plant preparations are widely used in the
prevention and treatment of common cold. However, so far no
molecular mechanism of action has been proposed. We analyzed
the standardized tincture EchinaforceTM and found that it
induced de novo synthesis of tumor necrosis factor a (TNF-a)
mRNA in primary human monocytes/macrophages, but not
TNF-a protein. Moreover, LPS-stimulated TNF-a protein was
potently inhibited in the early phase but prolonged in the late
phase. A study of the main constituents of the extract showed
that the alkylamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid
isobutylamides (1/2), trienoic (3) and dienoic acid (4) derivatives
are responsible for this eﬀect. The upregulation of TNF-a
mRNA was found to be mediated by CB2 receptors, increased
cAMP, p38/MAPK and JNK signaling, as well as NF-jB and
ATF-2/CREB-1 activation. This study is the ﬁrst to report a
possible molecular mechanism of action of Echinacea, highlight-
ing the role of alkylamides as potent immunomodulators and
potential ligands for CB2 receptors.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Echinacea; Tumor necrosis factor a; Cannabinoid
receptor CB2; Alkylamide; Immunomodulation1. Introduction
First used by Native Americans, the purple coneﬂower
(Echinacea purpurea and E. angustifolia) has become one of the
most popular phytomedicines and herbal supplements in
North America and Europe [1]. Echinacea preparations are
marketed and used worldwide to provide early treatment for
colds and as immunostimulants and belong to the best-selling
herbal medicines in the USA [2]. Preclinical studies lend bio-* Corresponding author. Fax: +41-1-6331366.
E-mail address: juerg.gertsch@pharma.ethz.ch (J. Gertsch).
Abbreviations: TNF-a, tumor necrosis factor a; MAPK, mitogen-
activated protein kinase; JNK, Jun N-terminal kinase; CB2, cannab-
inoid receptor 2; cAMP, cyclic adenosine monophosphate; CREB-1,
cAMP responsive element binding protein-1; ATF-2, activating
transcription factor-2; LPS, lipopolysaccharide; NF-jB, nuclear factor
jB; NF-AT, nuclear factor of activated T-cells; GM-CSF, granulocyte
colony stimulating factor; STAT-4, signal transducer and activator of
transcription-4; RANTES, regulated upon activation, normal T-cell
expressed and secreted; M/s, macrophages; PBMCs, peripheral blood
mononuclear cells; NK-cells, natural killer cells
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doi:10.1016/j.febslet.2004.10.064logical plausibility to the idea that Echinacea might work
through immune mechanisms [3,4]. Several clinical trials have
been carried out with Echinacea preparations and it appears
that certain preparations shorten the duration and severity of
colds and other upper respiratory tract infections, when given
as soon as the symptoms become evident [1,5,6]. Despite these
beneﬁts, the therapeutic potential of Echinacea is controversial
[7,8] and many published clinical trials have produced negative
results [9,10].
It is well known that the phytochemical proﬁles of distinct
Echinacea products are highly variable, depending on the
harvested plant material and extraction protocols [11]. So far,
no molecular mechanism of action has been proposed, which
makes a rational comparison of clinical trials with diﬀerent
Echinacea products virtually impossible.
Previous in vitro investigations with distinct Echinacea ex-
tracts have reported stimulatory eﬀects on macrophages (M/s)
[4,12], activation of natural killer cells (NK-cells) [13], as well
as non-speciﬁc induction of pro-inﬂammatory cytokines in
monocytes and M/s [14,15]. These eﬀects have, however, not
been correlated to a molecular mechanism of action. Because
contamination with lipopolysaccharide (LPS) endotoxins is a
problem in many preparations, it is not possible to interpret
such ﬁndings if the endotoxin content of the extracts has not
previously been determined [15]. In our study, we employed
clinically relevant concentrations (10–25 lg/mL) of the stan-
dardized Swiss registered E. purpurea (L.) Moench fresh plant
tincture EchinaforceTM (Ech) (endotoxin <0.5 EU/ml). The
same tincture has been used previously in a randomized dou-
ble-blind clinical study and showed signiﬁcant beneﬁt in the
treatment of common cold [5].
In order to understand which compounds are involved in the
Ech-induced TNF-a modulation reported here, we studied the
main constituents of Ech individually. For the ﬁrst time, we
show that dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutyla-
mides (1/2), trienoic (3) and dienoic acid (4) derivatives are
responsible for the described TNF-a mRNA upregulation and
inhibition of LPS-stimulated TNF-a protein synthesis. Due to
structural and functional similarities between the Echinacea
alkylamides (Fig. 4) and the endocannabinoids anandamide
(arachidonyl-ethanolamine) and 2-arachidonoyl-glycerol (2-
AG), an emerging class of natural modulators of TNF-a
expression, we put forward the hypothesis that cannabinoid
receptor 2 (CB2) could be the target of these compounds. As
described below, CB2 receptors and ligands (endocannabi-
noids) are expressed primarily in the periphery, especially ination of European Biochemical Societies.
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ceptors are G protein-coupled receptors (GPCRs), and they
have been linked to signaling pathways and gene activities in
common with this receptor family. In the last years,
(endo)cannabinoids have been shown to potentially modulate
a variety of immune cell functions in humans and animals
[16,17]. Furthermore, endocannabinoids have also been re-
ported to inhibit LPS-stimulated and endogenous TNF-a ex-
pression in monocytes/M/s, as well as in animal models
[18,19]. Anandamide, an endogenous CB2 agonist, can be
produced rapidly from circulating blood cells by LPS during
septic shock [20]. 2-AG, which is considered to be the true
natural ligand for CB2 [21], potently inhibits the release of
TNF-a from M/s in vitro and in vivo [22] and further en-
hances the production of IL-8 in HL-60 cells [21,23]. It was
recently shown that endocannabinoids ablate the release of
TNF-a in glial cells [24]. Interestingly, the same study reported
that the CB2 antagonist SR144528 increased TNF-a mRNA.
Thus, modulation of TNF-a through cannabinoid receptors
appears to be a versatile mechanism in diﬀerent immune cells.
We found that the Echinacea alkylamide-induced eﬀect in
monocytes/M/s was coupled to the regulation of cyclic
adenosine monophosphate (cAMP), which was sensitive to
pertussis toxin (PTX). Furthermore, the speciﬁc CB2 antago-
nist SR144528 potently abolished the alkylamide-induced
TNF-amRNA, whereas the speciﬁc CB1 antagonist SR147778
remained largely ineﬀective. PTX completely abolished the
upregulation. Our attempt to track down the eﬀect to a mo-
lecular mechanism of action revealed that several signal
transduction pathways are involved.2. Materials and methods
2.1. Reagents
The E. purpurea tincture EchinaforceTM (Ech) (batches 006338B,
0010916 and 006398) was obtained from A. Vogel Bioforce AG
(Switzerland). Ech was tested for endotoxin contamination by
Cambrex Corporation (International). SR144528 and SR147778 were
obtained as a gift from Sanoﬁ-Synthelabo Recherche (France). The
kinase inhibitors PD98059, U0126, SB203580, SB202190 and
SP600125 were obtained from Tocris Cookson Ltd. (UK). The al-
kylamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (1/
2), an isomer pair that could not be separated, dodeca-2E,4E,8Z-tri-
enoic acid isobutylamide (3), and dodeca-2E,4E-dienoic acid isobu-
tylamide (4) were isolated as published previously [25]. 1H and 13C
NMR (300 MHz Bruker) were measured and compared to the litera-
ture. Chlorogenic acid and cichoric acid were obtained from Phyto-
chem GmbH (Germany). LPS (Escherichia coli, phenol extraction
quality), pertussis toxin (PTX), actinomycin D (ActD) and forskolin
were purchased from Sigma (Switzerland), parthenolide was obtained
from Dr. W. Sch€uhly (Graz, Austria) and checked by 1H NMR, CB2Table 1
Primers and TaqManTM probes used in the real-time PCR experiments
Transcript
(GenBankTM No.)
Forward primer (50–30) Reverse p
STAT-4 (NM 003151.2) GCTGAGAGCTGTAGTGTTTACCGA AATAAAG
COX-2 (NM 000963) GAATCATTCACCAGGCAAATTG CTCGTAC
IL-8 (NM 000584) TTGGCAGCCTTCCTGATTTC TATGCAC
RANTES (AF043341) TCCCGAACCCATTTCTTCTCT CCCAGCA
TNF-a (NM 000594)f CCCAGGGACCTCTCTCTAATC ATGGGCT
IL-1b (NM 000576) CTGATGGCCCTAAACAGATGAAG GGTCGGArabbit polyclonal antibody (ab3561) and JNK1+ JNK2 (phospho
T183 and phospho Y185) antibodies were purchased from Abcam
(UK). Stock solutions (2 mM) of each drug were prepared in dimethyl
sulfoxide (DMSO) and then diluted in the appropriate buﬀer.
2.2. Cell isolations and cultures
Freshly isolated peripheral blood mononuclear cells (PBMCs) sep-
arated on PolymorphprepTM (Axis Shield, UK) and lymphocytes
separated on LymphoprepTM (Axis Shield, UK) were cultured in
RPMI 1640 medium (Life Technologies, Switzerland) supplemented
with 10% fetal bovine serum (FBS), 1 g/ml fungizone (amphotericin B),
100 U/ml penicillin, 100 g/ml streptomycin and 2 mM L-glutamine (all
from Life Technologies, Switzerland)] at 37 C and 5% CO2 in 50 ml
culture ﬂasks (TPP, Falcon). M/s enriched cultures were obtained by
overnight adhesion to glass plates in fresh RPMI-1640 medium. In the
experiments, the total solvent (DMSO/EtOH) content never exceeded
0.3% and no eﬀects were detected with a solvent control only. To di-
minish variability and pipetting errors, three wells were ﬁnally pooled
for RNA extraction to one experiment with 1.5 106 cells.
2.3. Reverse transcription TaqManTM real-time PCR (RT-rt-PCR)
Reverse transcription TaqManTM real-time PCR experiments were
performed as described previously [26,27]. Depending on the experi-
ment (see ﬁgures), CT-values were normalized to the house-keeping
gene GAP-DH. Primer and probe sequences used are shown in Table
1. The primer and probe sequences for IL-2, IL-6, granulocyte colony
stimulating factor (GM-CSF), iNOS, b-actin, p65, Ij-B, and nuclear
factor of activated T-cells (NF-ATc) have been published previously
[26,27].
2.4. cAMP accumulation assays
PBMCs (1 · 106) were washed and preincubated with HBSS sup-
plemented with 10 mM HEPES and 4 mM NaHCO3 (pH 7.5) for 5
min at 37 C. Reactions were initiated by the simultaneous addition of
forskolin (1 lM) and alkylamides to a ﬁnal assay volume of 600 ll.
Rolipram (50 lM) was added 5 min before the initiation of the reac-
tions to prevent degradation of accumulated cAMP. Alkylamides were
dissolved in DMSO. Dilutions were made in HBSS with 50 mg/ml fatty
acid-free bovine serum albumin. DMSO, equivalently diluted in HBSS,
served as a vehicle control and had no eﬀect on cAMP accumulation or
forskolin-stimulated cAMP accumulation. cAMP accumulation was
measured after 10 min incubation at 37 C. Reactions were terminated
by aspiration of the medium and the addition of 500 ll ice-cold eth-
anol. The ethanol extracts were dried under N2-gas and reconstituted
in acetate buﬀer. cAMP concentrations were quantiﬁed using Flash-
Plates (NEN, Boston, MA).
2.5. ELISA TNF-a quantiﬁcations
The hTNF-a ELISA (Roche Diagnostics GmbH, Germany) was
performed according to the manufacture’s instructions (procedure for
cell culture supernatants) together with the necessary controls. Ab-
sorbances were measured at 450 nm (reference wavelength at 570 nm)
on a 96-well plate reader (Dynex Technologies MRX).
2.6. TNF-a intracellular staining with FACS
Cell cultures were stimulated with LPS for 3 h prior to measure-
ment. For ﬁxation, the cell pellet was resuspended in 250 ll of Cy-
toﬁx/Cytoperm PlusTM (BD Pharmingen, Switzerland) and stored at
4 C in the dark for 10 min. Thoroughly resuspended, ﬁxed and
permeabilized cells (100 ll) were mixed with 10 ll per tube of phy-rimer (50–30) TaqManTM probe (50-Fam) (50–30)
GCCGGTTGTCTGCT AGTCTCGCAGGATGTCAGCGAATGG
TGCGGGTGGAACA TCCTACCACCAGCAACCCTGCCA
TGACATCTAAGTTCTTTAGCA CCTTGGCAAAACTGCACCTTCACACA
GTCGTCTTTGTCA TTGGCACACACTTGGCGGTTCTTC
ACAGGCTTGTCACT TGGCCCCAGGCAGTCAGATCATC
GATTCGTAGCAGCTGGAT TTCCAGGACCTGGACCTCTGCCCTC
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controls (BD Pharmingen, Switzerland) and incubated at 4 C in the
dark for 30 min. After incubation, cells were washed twice with
Perm/Wash-Buﬀer (BD Pharmingen) and resuspended in 300 ll of
staining buﬀer. Flow cytometric measurements were performed with
FACS-Scan (Becton–Dickinson) and software Cellquest 3.3. FITC
CD14þ-labeled monocytes/M/s were identiﬁed by immunﬂuorescence
(Fig. 5). At least 20 000 CD14þ monocytes were analyzed per sample.
For measuring intracellular cytokines with PE-labeled antibodies,
monocytes were gated from CD14þ cells. Unstimulated samples as
well as isotype controls (PD Pharmingen, Switzerland) were used as
negative controls.
2.7. CB2 and JNK1/2 immunoblotting
For the lysates generated in the phospho-JNK1/2 experiments, 100
lg was separated on an 8% SDS–PAGE gel, then transferred to PVDF
(2.5 h, 500 mA). Blocking of membranes and antibody dilutions was
performed according to the manufacturer’s directions. Membranes
were stripped (62.5 mM Tris, pH 6.8, 2% SDS, and 100 mM b-
mercaptoethanol; 55 C, 30 min) and reprobed for total protein.
Proteins were detected using an enhanced chemoluminescent reagent
(ECL). For the CB2 Western blot, resolved proteins were electro-
transferred to polyvinylidene diﬂuoride membrane in 192 mM glycine/
25 mM Tris (pH 8.8). For blotting, membranes were blocked using 5%
non-fat milk in PBS for 1 h at room temperature. Primary Abs were
dissolved in PBS/0.05% Tween 20/0.05% NaN3 and incubated with
membranes for 16 h at 4 C. Developing Abs comprised anti-rabbit
IgGs conjugated to HRP (Amersham Biosciences, Switzerland). These
were diluted to 0.1 lg/ml in PBS/0.05% Tween 20 and incubated with
membranes for 45 min at room temperature. A standard washing
protocol (four washes of 5 min in 50 ml of PBS/0.1% Tween 20 at room
temperature) was used between primary and secondary Abs and fol-
lowing secondary Ab. Signal was visualized using ECL.
2.8. Mercury transfactor assays
Nuclear extracts were made from lysates obtained from 5 106 cells
with Transfactor extraction kit (Clonetech laboratories Inc., USA),
according to the manufacturer’s instructions. Nuclear extracts were
then subjected to ELISA analysis with the TransFactorTM proﬁling kit
(Inﬂammation I) together with the necessary controls on a 96-well
plate. Signals were evaluated at 655 nm on a 96-well plate reader
(Dynex Technologies MRX).
2.9. Blocking with CB2 antagonists and kinase inhibitors
The cannabinoid receptor antagonists SR144528 and SR147778
were obtained from Sanoﬁ Synthelabo (France). The kinase inhibi-
tors were purchased from Tocris Cookson Ltd. (UK) and experi-
ments were performed with concentrations consisting in two times the
IC50 values reported by the manufacturer. The nuclear factor jBTable 2
Eﬀect of 25 lg/ml EchinaforceTM on mRNA proﬁles in peripheral blood leu
Gene (GenBankTM No.) Regulation (fold) Function
b-Actin (NM001101) +2.9 0.7 House-keepin
GAP-DHa +0.7 0.5 House-keepin
Cyclin D1 (XM006138) +0.8 0.6 Cell-cycle
P65 (RelA) (M62399) +0.9 0.8 NF-jB
I-jBa (M83221) +1.2 0.6 NF-jB
STAT-4 (NM 003151.2) +0.9 0.2 Signal transd
IL-1b (NM 000576) +1.9 0.7 Cytokine
IL-2 (S77834) )2.4 0.8 Cytokine
IL-6 (M54894) +1.1 0.9 Cytokine
IL-8 (NM 000584) +3.7 0.6 Cytokine/Che
RANTES (AF043341) +0.9 0.4 Cytokine
GM-CSF (M10663) +0.8 0.6 Growth facto
iNOS (L09210) +0.9 0.5 Inﬂammation
TNF-a (NM 000594) +11.3 2.3 Cytokine
COX-2 (NM 000963) +0.5 0.6 Inﬂammation
NF-AT (XM006883) +3.3 0.7 Transcription
IFN-c (XM006883) +0.9 0.7 Interferon
3 106 cells were incubated with EchinaforceTM for 24 h. mRNA levels wer
three experiments performed in duplicate with cells from three blood donors
aGAP-DH was purchased from PE Biosystems.(NF-jB) inhibitor parthenolide was used at 5 lM. All inhibitors were
incubated 1 h prior to stimulation with alkylamides. Inhibitors and
test compounds (alkylamides) were incubated for a total of 22 h prior
to RT-rt-PCR.3. Results
3.1. Eﬀect of EchinaforceTM (Ech) on peripheral blood
leukocyte mRNA levels – speciﬁc de novo TNF-a
mRNA synthesis
In an attempt to elucidate the possible immunomodula-
tory potential of Echinacea, we ﬁrst studied its eﬀect on the
expression of key genes with RT-rt-PCR as described before
[27]. In this system, we compared the mRNA levels prior to
and after stimulation of cells with clinically relevant con-
centrations (10–25 lg/ml) of Ech. We repeatedly found a
strong induction of TNF-a (>11-fold) (Table 2), which was
not due to particle stimulation of undissolved matter in the
tincture, nor endotoxin contamination. Also b-actin, NF-
ATc and IL-8 were signiﬁcantly upregulated, whereas the
constitutive IL-2 expression was downregulated.
We then investigated which fractions of our leukocyte
population were responsible for the eﬀect on TNF-a. Density-
gradient separated granulocytes, T-lymphocytes, and mono-
cytes/Ms were separately incubated with 25 lg/ml of Ech and
analyzed with RT-rt-PCR. Only the monocyte/M/ fraction
showed a strong time and concentration-dependent upregula-
tion of TNF-a mRNA (Fig. 1). To assess whether the upreg-
ulation was due to de novo synthesis (transcription) or
stabilization of the transcripts, we performed co-incubation
experiments with the transcription inhibitor ActD. ActD
strongly inhibited the upregulation (Fig. 1), which led to the
conclusion that Echinacea caused de novo synthesis of TNF-a
in monocytes/M/s.3.2. Kinetic study of immunomodulatory eﬀect on TNF-a
expression in monocytes/M/s
ELISA measurements of culture supernatants (Fig. 2) and
FACS intracellular staining (not shown) demonstrated that nokocytes
Main expression in PBMCs
g Ubiquitous
g Ubiquitous
Ubiquitous
Ubiquitous
Ubiquitous
uction Ubiquitous
Monocytes/M/s, B-cells
T helper cells, T-cells
Monocytes/M/s
motaxis Monocytes/M/s, Ubiquitous
T cells, epithelial cells
r Th cells, granulocytes, M/s
Ubiquitous
Monocyes/M/s, Th, B cells
Monocytes
factor Th cells, monocytes/Ms
Th cells, NK-cells, cytotoxic T
e relatively quantiﬁed by RT-rt-PCR. Data are meansS.E.M. from
. Data are not normalized to a house-keeping gene.
Fig. 1. Concentration and time-dependent eﬀect of EchinaforceTM
(Ech) on TNF-a mRNA in monocytes/M/s enriched PBMCs. 2 106
cells were treated with 25 lg/ml (black bars), 15 lg/ml (gray bars) and
10 lg/ml (white bars) Ech and TNF- mRNA was quantiﬁed by RT-rt-
PCR. The experiment was also performed with 24 h co-incubation of
ActD (2 lM). ActD was added 1 h prior to stimulation with Ech. Data
(+S.E.) represent three independent experiments performed in dupli-
cate with cells from diﬀerent blood donors. TNF-a CT values were
normalized to GAP-DH. A diﬀerence of 6 2-fold is signiﬁcant.
Fig. 2. Kinetic study showing TNF-expression in primary human
monocytes/M/s enriched PBMCs (3 106 cells) from peripheral blood
as mRNA (A) and protein levels (B), respectively, over a time course of
39 h. Ech (25 lg/ml) and LPS (1 lg/ml) were both tested alone and in
combination.Echwas incubated 1 h before addition ofLPS. ThemRNA
levels were determined by RT-rt-PCR (normalized to GAP-DH) and
protein concentrations by ELISA. Data points were obtained every 3 h
and are mean valuesS.E. from three independent experiments.
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Ech-induced TNF-a transcripts were not translated. Because
LPS induces CD14þ-mediated signaling in monocytes/M/s,
we tested whether co-incubation with LPS as the second signal
might lead to superinduction of TNF-a protein. Interestingly,
LPS mediated TNF-a protein expression on the contrary was
strongly inhibited (Fig. 2).
Due to rapid and complex regulations of TNF-a expression
in monocytes/M/s [28] we carried out parallel kinetic experi-
ments measuring both mRNA and protein levels over a time-
span of 39 h. Our analysis was carried out with unstimulated
controls, Ech or LPS-stimulated cell populations only, as well
as in combination. TNF-a mRNA was upregulated (8-fold)
by 25 lg/ml Ech over a time-span of 24 h (Fig. 2A), whereas
the constitutive protein level was not modulated (Fig. 2B). In
Ech plus LPS-stimulated cells, the mRNA levels were only
modulated after 24 h and Ech treatment prevented the rapid
decay of transcripts seen with LPS-stimulated cells. On the
other hand, LPS-stimulated TNF-a protein expression was
potently modulated by Ech, resulting in signiﬁcant inhibition
(40%) during the ﬁrst 20 h and subsequent prolongation of
TNF-a protein expression (Fig. 2B). The observed eﬀects on
TNF-a protein might be related to intrinsic feedback signaling.
Therefore, LPS-mediated autoregulatory functions of TNF-a
expression in monocytes/M/s were strongly modulated by Ech
and this suggested an underlying molecular mechanism of
action related to speciﬁc but hitherto undeﬁned bioactive
principles in the tincture.
3.3. Alkylamides are the active principles in Echinacea
A systematic investigation of the main secondary metabo-
lites in Ech tincture ﬁnally showed that the major alkylamides,
namely dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutyla-
mides (1/2) and trienoic (3) and dienoic acid (4) derivatives
(Fig. 3), upregulated TNF-a mRNA levels at nanomolar
concentrations (Fig. 4). Cichoric acid and chlorogenic acid did
not inﬂuence the constitutive levels of pro-inﬂammatory cy-
tokines. Also, the polar fraction containing residual oligosac-
charides was inactive (Fig. 4). This clearly indicated that the
biogenic class of alkylamides exhibits immunomodulatoryFig. 3. Structures of the isolated alkylamides studied: (1/2) isomer pair
dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide and dodeca-
2E,4E,8Z,10Z-tetraenoic acid isobutylamide, (3) dodeca-2E,4E,8Z-
trienoic acid isobutylamide, and (4) dodeca-2E,4E-dienoic acid
isobutylamide.
Fig. 4. Induction of TNF-a mRNA in monocytes/M/s by 1/2, 3, 4,
cichoric acid, chlorogenic acid, and a polar fraction containing residual
Ech oligosaccharides measured by RT-rt-PCR (normalized to GAP-
DH). Diﬀerences >2-fold are signiﬁcant. White bars: 0.5 lM (polar
fraction 0.5 ppm) of test compounds, gray bars: 5 lM (polar fraction 5
ppm) incubated with 2 106 cells for 22 h prior to RT-rt-PCR
analysis. Data represent mean values S.E. of two independent
experiments.
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induced eﬀect on TNF-a.
To assess whether the LPS-stimulated TNF-a expression
was inhibited by alkylamides, as this was found with Ech, we
quantiﬁed the protein content by FACS intracellular staining.
Our results show that the alkylamides 1/2 (5 lM) potently
inhibit TNF-a protein expression (Fig. 5).
Due to structural and functional similarities between the
Echinacea alkylamides and the endocannabinoids anandamide
and 2-AG, we put forward the hypothesis that CB2 receptors
might be the target of these compounds. We therefore exam-
ined whether PTX, which is an inhibitor of GPCRs, couldFig. 5. FACS histograms of one representative experiment demonstrate a de
incubation with 1/2 and subsequent stimulation with LPS (1 lg/ml) for 3 h.
stimulation, (C) illustration of gating strategy: gating of monocytes/M/s baabolish the alkylamide-induced TNF-a mRNA upregulation.
Fig. 6A shows that PTX (0.5 and 1 lM) potently inhibited the
eﬀect. We then decided to further follow up our hypothesis.
3.4. CB2 receptors are expressed on monocytes/M/s and play a
prominent role for the eﬀect exerted by alkylamides
To ascertain that CB2 was the receptor subtype involved
in the observed eﬀects, as for the studies on TNF-a gene
expression in monocytes/M/s, the CB2 antagonist
SR144528 and CB1 antagonist SR147778 were used in
combination with the alkylamides 1/2. Fig. 6A shows that
only the CB2 speciﬁc antagonist abolished the TNF-a
transcription and thus indicated a strict peripheral cannab-
inoid-mediated process. Therefore, the alkylamides 1/2 ap-
pear to mediate an agonistic signal via CB2 receptors that
can be blocked by SR144528. Western blot analysis of T-
lymphocyte and monocyte/M/ fractions used in our ex-
periments further conﬁrmed the expression of CB2 on
monocytes/M/s (Fig. 6B). Additional studies will have to
show whether alkylamides directly regulate the expression of
CB2 receptors.
3.5. Alkylamides modulate cAMP
To assess whether constitutive and forskolin-stimulated
cAMP levels were inﬂuenced by alkylamides, as suggested by
the involvement of CB2 receptor and structural similarities to
endocannabinoids, we co-incubated 1 lM of 1/2 with mono-
cytes/M/s and subsequently measured the cytoplasmic cAMP
levels. 1/2 signiﬁcantly upregulated constitutive cAMP and
moderately inhibited forskolin-stimulated cAMP (Fig. 7).
cAMP induced by 1/2 was inhibited by PTX (1 lM), which
again conﬁrmed the participation of G-protein coupled CB2
receptors.creased expression of TNF-a in primary human monocytes/M/s after
(A) LPS stimulated cells, (B) incubation with 1/2 (5 lM) prior to LPS
sed on immunoﬂuorescence (CD14þ FITC positive cells).
Fig. 8. Co-incubation with diﬀerent kinase inhibitors incubated 1 h
prior to monocyte/M/s stimulation with 1/2 (5 lM). Concentrations
used were twice IC50 reported by manufacturer (Tocris Cookson Ltd.).
Parthenolide were used at 5 lM. Shown is (%)-inhibition (mean S.E.)
of the 1/2-induced eﬀect described in Fig. 3. Data are mean values
(S.E.) of four experiments (two diﬀerent blood donors).
Fig. 9. Representative anti-p-JNK1 and anti-p-JNK2 Western blot
(8% SDS–PAGE) showing a time-dependent phosphorylation of JNK
by 1/2 (5 lM).
Fig. 6. Speciﬁc CB receptor antagonists were incubated 1 h prior to monocyte/M/s stimulation with 1/2 (5 lM for 22 h). The CB1 antagonist
SR147778 (white bar: 1 lM, gray bar: 10 lM) did not markedly inhibit the eﬀect on TNF-a mRNA induced by 1/2 (Fig. 3), whereas the CB2
antagonist SR144528 (white bar: 1 lM, gray bar: 10 lM) and PTX (white bar: 0.5 lM, gray bar: 1 lM) strongly abolished the eﬀect. Data are mean
values (+S.E.) of three independent experiments. (B) Immunoblot of anti-CB2 separated on 10% SDS–PAGE shows that CB2 is not only well
expressed on primary monocyte/M/s (1), but also on primary lymphocytes (2).
Fig. 7. cAMP levels in human PBMCs measured as described under
Section 2. 1 lM 1/2 induced an increase (166%) (2) in cAMP relative to
constitutive levels (1) and moderately inhibited (44%) (4) forskolin (2
lM)-stimulated cAMP accumulation (289% relative to untreated
control) (3). PTX (1 lM) inhibited alkylamide-induced cAMP com-
pletely (5). Data show mean values of three independent experiments
(S.E.).
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activated protein kinase (MAPK)/p38 signaling pathways
To track down the alkylamide-induced eﬀect on TNF-a
transcription, we employed speciﬁc signal transduction path-
way inhibitors. We used the MAPK/MEKK inhibitor
PD98059, MEK1/2 inhibitor U0126, p38/MAPK inhibitors
SB203580 and SB202190, the JNK inhibitor SP600125 and the
NF-jB inhibitor parthenolide. As shown in Fig. 8, the JNK
speciﬁc inhibitor SP600125 and p38/MAPK speciﬁc inhibitors
SB203580 and SB202190, respectively, very potently inhibited
the alkylamide-induced TNF-a transcription. Parthenolide (5
lM) also signiﬁcantly inhibited the upregulation and thus in-
dicated that NF-jB was a possible factor involved. MEK1/2
seems to play a function though to a lesser degree (Fig. 8).
JNK1/2 phosphorylation and thus involvement of this kinase
was further conﬁrmed by Western blot analysis (Fig. 9).
3.7. Alkylamide-induced TNF-a transcription is mediated by
NF-jB, ATF-2 and CREB-1
In order to study the signaling downstream of the kinases,
we employed sensitive ELISA-based MercuryTM transfactor
assays as described under Section 2. This allowed us to study
the degree of activation (nuclear protein capable of DNA-binding) of relevant transcription factors involved in the al-
kylamide-induced TNF-a gene induction. NF-jB, ATF-2 and
cAMP response element binding protein (CREB-1) were sig-
niﬁcantly activated (Fig. 10). Interestingly, NF-jB induced by
LPS was inhibited by alkylamides (data not shown). It has
previously been shown that cannabinoid receptors can signal
to NF-jB via cAMP [29]. ATF-2 is a CRE-binding factor and
also known to be involved in TNF-a expression as ATF-2/Jun
complex [30]. We conclude that these transcription factors are
Fig. 10. Activation of transcription factors measured with Mercury
transfactor assays. Nuclear extracts of 1/2-treated (5 lM for 16 h)
monocytes/M/s (5 106 cells) were subjected to ELISA and activation
(dotted bars) was measured relative to untreated controls (white bars).
Data represent mean values of three independent experiments S.E.
J. Gertsch et al. / FEBS Letters 577 (2004) 563–569 569directly involved in TNF-a transcription induced by
alkylamides.4. Discussion
Despite huge investments into the clinical evaluation of
distinct Echinacea products, the molecular mechanism of ac-
tion has remained a riddle. It is important to emphasize that
many of the reported eﬀects for Ech on the cellular immune
system parallel the eﬀects seen with LPS. These ﬁndings show
the absolute need for standardized and endotoxin-free prepa-
rations for in vitro experiments. Here, we report on the potent
modulatory action of Echinacea alkylamides on TNF-a ex-
pression in human monocytes/M/s. It is shown that this eﬀect
is mediated via the cannabinoid receptor CB2 and that mod-
ulation of cAMP, activation of JNK and p38/MAPK kinases,
as well as downstream activation of ATF-2/CREB-1 and NF-
jB are involved. The ﬁnding that alkylamides are the likely
immunomodulatory principles of Echinacea is of great interest
for further clinical studies with this medicinal plant. We believe
that the unequivocal outcome of diﬀerent clinical trials with
Echinacea is in part derived from diﬀerences in quality of the
used preparations. Alkylamides have previously been shown to
be absorbed and nanomolar quantities have been detected in
the blood of patients after oral application [31], which further
qualiﬁes these compounds as the bioactive principles.
It is interesting to note that although Echinacea alkylamides
induce TNF-a mRNA, which is not translated, they inhibit
LPS-stimulated TNF-a protein expression too. This dual
modulation on the non-speciﬁc immune response may also
explain previous reports on the anti-inﬂammatory action of
Echinacea preparations [32]. Since TNF-a is a strong endoge-
nous signal with multiple autoregulatory mechanisms in dif-
ferent cell types, and a broad spectrum of physiological roles,
our ﬁnding that Echinacea alkylamides modulate this factor
via CB2 receptors might open up new avenues in Echinacea
research.
In order to address the question whether the here reported
TNF-a modulation might be physiologically relevant for the
indicated use of Echinacea, further studies are required. We are
currently studying the nature of alkylamide interactions with
the CB2 receptor by computational homology docking studies
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